Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
作者信息
Wright Karen L, Robertson Duncan A F, Moyer Mary P, Ward Stephen G
出版信息
Int J Cancer. 2008 Apr 15;122(8):1920-1. doi: 10.1002/ijc.23304.
PMID:18076045
Abstract
摘要
相似文献
1
Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Int J Cancer. 2008 Apr 15;122(8):1920-1. doi: 10.1002/ijc.23304.
2
Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".
Int J Cancer. 2008 Jul 1;123(1):243-4. doi: 10.1002/ijc.23507.
3
Rimonabant, obesity and diabetes.
Prescrire Int. 2007 Jun;16(89):122.
4
How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
Drug Discov Today. 2010 Jun;15(11-12):411-5. doi: 10.1016/j.drudis.2010.04.004. Epub 2010 May 4.
5
[Rimonabant (Acomplia)].
J Pharm Belg. 2008 Mar;63(1):27-8.
6
End of the line for cannabinoid receptor 1 as an anti-obesity target?
Nat Rev Drug Discov. 2008 Dec;7(12):961-2. doi: 10.1038/nrd2775.
7
[The endocannabinoid system and treatment of obesity].
Tidsskr Nor Laegeforen. 2008 Feb 28;128(5):570-1.
8
Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):610-2. doi: 10.1038/ncpcardio1319. Epub 2008 Aug 12.
9
Effect of rimonabant on weight and cardiometabolic risk factors.
JAMA. 2006 Aug 9;296(6):649-50; author reply 650-1. doi: 10.1001/jama.296.6.649.
10
The effect of am 251, a cannabinoid CB1 receptor antagonist, on food intake in rats.
Acta Pol Pharm. 2004 Sep-Oct;61(5):401-3.
Zotero 插件